Teva Pharma (TEVA) Announces U.S. Launch of its Generic Version of SOOLANTRA Cream, 1% for Once Daily Treatment of Rosacea

June 16, 2021 7:37 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the U.S. launch of its generic version of once daily SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.

With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

SOOLANTRA® had annual sales of more than $115 million in the U.S., according to IQVIA data as of April 2021.

About Ivermectin Cream 1%

Ivermectin cream, 1% is a prescription medicine used for the treatment of inflammatory lesions of rosacea.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Related Entities

Definitive Agreement, FDA